A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature

scientific article

A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.EURONEURO.2015.08.019
P698PubMed publication ID26527055
P5875ResearchGate publication ID282835623

P50authorJoseph ZoharQ21104323
Stephen StahlQ24006564
Pierre U. BlierQ46045677
Shigeto YamawakiQ92663506
Hans-Jürgen MöllerQ1577771
David KupferQ5236159
Guy M. GoodwinQ5622285
P2093author name stringMichael Spedding
David Nutt
Hiroyuki Uchida
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectneuroscienceQ207011
P304page(s)2318-2325
P577publication date2015-09-07
P1433published inEuropean NeuropsychopharmacologyQ15286536
P1476titleA review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature
P478volume25

Reverse relations

cites work (P2860)
Q42399356A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents
Q47750718A new nomenclature for classifying psychotropic drugs
Q38665865Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.
Q92476399Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-Nomenclature
Q92218063Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis
Q37035659Classification of psychotropic drugs: Problems, solutions, and more problems
Q48046839Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants
Q92850928Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis
Q38797653Drugs, games, and devices for enhancing cognition: implications for work and society
Q33716263Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
Q56962426Major depressive disorder
Q28066691Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Q42828114Neuroscience-based Nomenclature (NbN) for Clinical Psychopharmacology and Neuroscience
Q48561791Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology
Q42379069Neuroscience-based Nomenclature (NbN): A call for action
Q42131810Neuroscience-based nomenclature and medicolegal significance
Q37730207New drugs in psychiatry: focus on new pharmacological targets
Q42392349Prescribing according to diagnosis: how psychiatry is different
Q64082982Prognosis and improved outcomes in major depression: a review
Q48536218Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications
Q39487850Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study
Q96028604Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition
Q34530580Suicide prevention strategies revisited: 10-year systematic review
Q58586423Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
Q47985236The in vitro actions of loxapine on dopaminergic and serotonergic receptors. Time to consider atypical classification of this antipsychotic drug?
Q38957224Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding
Q87708998Using neuroscience for naming psychotropic drugs
Q90191620What do patients learn about psychotropic medications on the web? A natural language processing study
Q57056580What's in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology

Search more.